Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting
Source abstract
Abstract
BioNTech/Pfizer's Comirnaty and Moderna's SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · 3D Printing in Biomedical Research · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (81)
Show source-provided references
1. The way of SARS-CoV-2 vaccine development: success and challenges
2. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
3. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-210.1038/s41541-021-00336-1 ↗
4. Nanomaterial delivery systems for mRNA vaccines10.3390/vaccines9010065 ↗
5. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-210.1016/j.biopha.2021.111953 ↗
6. Middle east respiratory syndrome: obstacles and prospects for vaccine development10.1586/14760584.2015.1036033 ↗
7. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations10.1080/10717540490265243 ↗
8. Influence of cholesterol on liposome stability and on in vitro drug release10.1007/s13346-015-0220-8 ↗
9. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines10.3109/10611869608996830 ↗
10. Next-generation lipids in RNA interference therapeutics10.1021/acsnano.7b04734 ↗
11. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering10.1021/acs.nanolett.9b04246 ↗
12. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes
13. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening10.1016/j.jconrel.2019.10.028 ↗
14. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs10.1038/s41565-019-0591-y ↗
15. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines10.3390/vaccines9040359 ↗
16. Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy10.1021/acs.jpcb.7b10795 ↗
17. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability10.1016/j.ijpharm.2021.120586 ↗
18. Biocompatible nanovector of siRNA consisting of arginine-based cationic lipid for gene knockdown in cancer cells
19. Efficient cellular knockdown mediated by siRNA nanovectors of gemini cationic lipids having delocalizable headgroups and oligo-oxyethylene spacers10.1021/acsami.6b08823 ↗
20. Highly efficient gene silencing activity of siRNA embedded in a nanostructured gyroid cubic lipid matrix10.1021/ja1059763 ↗
21. mRNA-based therapeutics—developing a new class of drugs10.1038/nrd4278 ↗
22. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles
23. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA
24. mRNA vaccine: a potential therapeutic strategy10.1186/s12943-021-01311-z ↗
25. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
26. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors10.1248/bpb.b13-00059 ↗
27. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
28. Current concepts in the diagnosis and management of cytokine release syndrome
29. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines10.1016/j.omtn.2019.01.013 ↗
30. A decade of the protein corona10.1021/acsnano.7b08008 ↗
31. Interplay of protein corona and immune cells controls blood residency of liposomes10.1038/s41467-019-11642-7 ↗
32. The importance of poly (Ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles10.3390/pharmaceutics12111068 ↗
33. Mechanistic understanding of gene delivery mediated by highly efficient multicomponent envelope-type nanoparticle systems10.1021/mp400470p ↗
34. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles10.1002/btm2.10213 ↗
35. Overcoming delivery barriers with LNPs10.1038/s41563-021-00988-3 ↗
36. Tailoring lipoplex composition to the lipid composition of plasma membrane: a Trojan horse for cell entry?10.1021/la1023899 ↗
37. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells10.1038/s41467-019-12275-6 ↗
38. Biological identity of nanoparticles in vivo: clinical implications of the protein corona10.1016/j.tibtech.2016.08.011 ↗
39. Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-210.1016/j.jconrel.2021.08.046 ↗
40. Advances in the biofabrication of 3D skin in vitro: healthy and pathological models10.3389/fbioe.2018.00154 ↗
41. Dynamics of nanoparticle diffusion and uptake in three-dimensional cell cultures10.1016/j.colsurfb.2016.09.046 ↗
42. New perspectives on the roles of nanoscale surface topography in modulating intracellular signaling10.1016/j.cossms.2020.100873 ↗
43. How do surface properties of nanoparticles influence their diffusion in the extracellular matrix? A model study in Matrigel using polymer-grafted nanoparticles10.1021/acs.langmuir.0c01624 ↗
44. Preventing obstructions of nanosized drug delivery systems by the extracellular matrix10.1002/adhm.201700739 ↗
45. Deconstructing the third dimension–how 3D culture microenvironments alter cellular cues
46. Three-dimensional cell culture models for investigating human viruses10.1007/s12250-016-3889-z ↗
47. Innovative human three-dimensional tissue-engineered models as an alternative to animal testing10.3390/bioengineering7030115 ↗
48. 3D tissue models as an effective tool for studying viruses and vaccine development10.3389/fmats.2021.631373 ↗
49. Bioengineered in vitro tissue models to study SARS-CoV-2 pathogenesis and therapeutic validation10.1021/acsbiomaterials.0c01226 ↗
50. An insight on advances and applications of 3d bioprinting: a review10.1016/j.bprint.2021.e00176 ↗
51. 3D printing of pharmaceutical application: drug screening and drug delivery10.3390/pharmaceutics13091373 ↗
52. High throughput direct 3D bioprinting in multiwell plates10.1088/1758-5090/ab89ca ↗
53. 3D graphene scaffolds for skeletal muscle regeneration: future perspectives10.3389/fbioe.2020.00383 ↗
54. Bioprinting of 3D in vitro skeletal muscle models: a review10.1016/j.matdes.2020.108794 ↗
55. Human tissue-engineered skeletal muscle: a novel 3D in vitro model for drug disposition and toxicity after intramuscular injection10.1038/s41598-018-30123-3 ↗
56. Engineering skeletal muscle: building complexity to achieve functionality
57. Incorporation of macrophages into engineered skeletal muscle enables enhanced muscle regeneration10.1038/s41551-018-0290-2 ↗
58. Vascularization of tissue-engineered skeletal muscle constructs10.1016/j.biomaterials.2019.119708 ↗
59. Microarray patches enable the development of skin-targeted vaccines against COVID-1910.1016/j.addr.2021.01.022 ↗
60. Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults10.1016/j.vaccine.2021.07.096 ↗
61. Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity10.1016/j.celrep.2020.02.111 ↗
62. Vaccine delivery systems toward lymph nodes10.1016/j.addr.2021.113914 ↗
63. Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling10.1038/nature25442 ↗
64. A novel sample holder for 4D live cell imaging to study cellular dynamics in complex 3D tissue cultures10.1038/s41598-018-28206-2 ↗
65. Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity10.1073/pnas.2102595118 ↗
66. 3D bioprinting for skin tissue engineering: current status and perspectives10.1177/20417314211028574 ↗
67. Toward immunocompetent 3D skin models10.1002/adhm.201701405 ↗
68. In vitro models mimicking immune response in the skin10.3349/ymj.2021.62.11.969 ↗
69. In vitro skin culture media influence the viability and inflammatory response of primary macrophages10.1038/s41598-021-86486-7 ↗
70. Construction of three-dimensional dermo–epidermal skin equivalents using cell coating technology and their utilization as alternative skin for permeation studies and skin irritation tests10.1089/ten.tea.2016.0529 ↗
71. Development of full‐thickness human skin equivalents with blood and lymph‐like capillary networks by cell coating technology10.1002/jbm.a.35473 ↗
72. Human skin 3D bioprinting using scaffold‐free approach10.1002/adhm.201601101 ↗
73. 3D bioprinting of functional human skin: production and in vivo analysis10.1088/1758-5090/9/1/015006 ↗
74. Development and characterization of a human Th17–driven ex vivo skin inflammation model10.1111/exd.14160 ↗
75. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination–a case report
76. Maternal and neonatal SARS‐CoV‐2 antibodies assessment after mRNA maternal vaccination in the third trimester of pregnancy10.1002/ijgo.13783 ↗
77. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy10.1080/21645515.2021.1947099 ↗
78. Bioengineered microphysiological placental models: towards improving understanding of pregnancy health and disease10.1016/j.tibtech.2021.03.009 ↗
79. Biomimetic placenta-fetus model demonstrating maternal–fetal transmission and fetal neural toxicity of zika virus10.1007/s10439-018-2090-y ↗
80. Inspired by the human placenta: a novel 3D bioprinted membrane system to create barrier models10.1038/s41598-020-72559-6 ↗
81. COVID-19 vaccines: where we stand and challenges ahead10.1038/s41418-020-00720-9 ↗